13.23
放出修飾型薬物送達システム：レートプログラム型 II
レートプログラム型薬物送達システムは、治療濃度を維持するために、薬物を制御された様式で放出します。主な設計には、リザーバーシステム、マトリックスシステム、およびハイブリッドシステムの3つがあります。
リザーバーシステムは、薬物放出を制御する膜で被覆された薬物コアから構成されます。非膨潤性リザーバーシ…
レートプログラムされた薬物送達システムは、リザーバー、マトリックス、またはハイブリッドの3つの設計を踏みます。
リザーバーシステムは、薬剤コアを速度制御膜または膜の中に包み込みます。
非膨張型は、エチルセルロースおよびポリメタクリレートポリマーを用いて、粘度、不溶性、緩やかな溶解、または多孔性による薬物放出を制御します。腫れ制御型は、HPMCのようなポリマーを使って膜の水分化まで薬物の放出を遅らせます。
マトリックスシステムは薬剤を放出遅延材料に埋め込みます。
親水性マトリックスはHPMCのような膨張性ポリマーを使用し、疎水性マトリックスはワックスやエチルセルロースを使用します。疎水性マトリックスは、薬物がポリマーに混ざる多孔質の場合もあれば、溶融ポリマー中に薬物が分散した非多孔性の行列もあります。
ハイブリッドシステムは、薬剤を放出遅延材料でコーティングされたマトリックスに埋め込み、さらに放出抑制ポリマーでコーティングします。この設計は、リザーバーシステムの安定放出とマトリックスデバイスの耐久性を組み合わせ、薬物放出を効果的に制御します。
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.